CD8A and prediabetes syndrome: We also found that activated CD8+CD28− T cells using anti-CD3 antibodies showed a higher ECAR in the patients with prediabetes than in normal controls (Fig. 4g), suggesting that metabolically higher glycolytic potential of CD8+CD28− T cells is visible in the patients with abnormal glucose homeostasis.